Core Insights - The AI Fund Qianhai Kaiyuan Medical Health A (005453) reported a profit of 57.04 million yuan for Q2 2025, with a weighted average profit per fund share of 0.123 yuan. The fund's net value growth rate was 12.63%, and the fund size reached 498 million yuan by the end of Q2 2025 [2][15]. Fund Performance - As of July 18, 2025, the fund's one-year cumulative net value growth rate was 47.58%, ranking 52 out of 133 comparable funds. Over the past three months, the growth rate was 39.80%, ranking 25 out of 138 [3]. - The fund's three-year Sharpe ratio was -0.3238, ranking 99 out of 105 comparable funds [8]. - The maximum drawdown over the past three years was 51.82%, with the highest quarterly drawdown occurring in Q3 2021 at 27.66% [10]. Investment Strategy - The fund focuses on flexible allocation, primarily investing in pharmaceutical and healthcare stocks. In Q2 2025, it emphasized investments in high-growth biotech companies and traditional pharmaceutical firms entering a harvest phase for innovative drugs. The fund manager anticipates continued demand for innovative drugs from overseas pharmaceutical companies due to the overseas patent cliff, alongside a surge in domestic supply of innovative drugs [2]. - The fund aims to enhance its research on industry fundamentals and macro trends, employing both top-down and bottom-up analysis methods for sector allocation and individual stock valuation assessments [2]. Fund Holdings - As of Q2 2025, the top ten holdings of the fund included companies such as Sanofi Pharmaceutical, Diligent Pharma, Innovent Biologics, and BeiGene, among others [18]. Fund Positioning - The average stock position over the past three years was 90.14%, with a peak of 93.11% at the end of H1 2025 and a low of 65.37% at the end of H1 2019 [13].
前海开源医疗健康A：2025年第二季度利润5704.41万元 净值增长率12.63%
Sou Hu Cai Jing·2025-07-21 10:40